The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein–producing gastric or gastroesophageal junction adenocarcinoma: A single-arm, multi-center, phase 2 trial.
 
Yakun Wang
No Relationships to Disclose
 
Chang Wang
No Relationships to Disclose
 
Xiaofeng Chen
No Relationships to Disclose
 
Zhi Peng
No Relationships to Disclose
 
Yanhong Gu
No Relationships to Disclose
 
Yizhuo Wang
No Relationships to Disclose
 
Xicheng Wang
No Relationships to Disclose
 
Jian Li
No Relationships to Disclose
 
Jifang Gong
No Relationships to Disclose
 
Changsong Qi
No Relationships to Disclose
 
Jiajia Yuan
No Relationships to Disclose
 
Zhihao Lu
No Relationships to Disclose
 
Ming Lu
No Relationships to Disclose
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Yanshuo Cao
No Relationships to Disclose
 
Lin Shen
No Relationships to Disclose
 
Xiaotian Zhang
No Relationships to Disclose